公开(公告)号：US20240109972A1

公开(公告)日：2024-04-04

申请号：US18038818

申请日：2021-12-07

Applicant: Genmab A/S ,  BioNTech SE

Inventor： Ugur SAHIN ,  Alexander MUIK ,  Ulf FORSSMANN ,  Maria JURE-KUNKEL ,  Manish GUPTA ,  Tahamtan AHMADI ,  Kathy AMIRI ,  Gaurav BAJAJ

IPC: C07K16/28 ,  A61K31/337 ,  A61K45/06 ,  A61P35/00

CPC classification number: C07K16/2878 ,  A61K31/337 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2827 ,  A61K2039/505

Abstract: The present invention provides combination therapy to reduce or prevent progression of a tumor or treating cancer in a subject. The combination therapy comprises administration of a binding agent that binds to human CD137 and to human PD-L1; and a taxane chemotherapeutic agent.

公开(公告)号：US20230087164A1

公开(公告)日：2023-03-23

申请号：US17795318

申请日：2021-02-04

Applicant: GENMAB A/S ,  BIONTECH SE

Inventor： Ugur SAHIN ,  Alexander MUIK ,  Isil ALTINTAS ,  Ulf FORSSMANN ,  Kate SASSER ,  Maria JURE-KUNKEL ,  Manish GUPTA

IPC: C07K16/28 ,  A61P35/00

Abstract: The present invention relates to a method for reducing or preventing progression of a tumor or treating cancer. The method comprises administering to a subject, a binding agent comprising a first binding region binding to human CD137 and a second binding region binding to human PD-L1. The amount of binding agent administered in each treatment cycle is preferably about 0.3-5 mg/kg body weight or about 25-400 mg in total.